ESC Preventive 2024 Premium Access

Percentage and main features of patients referred to a cardiac rehabilitation program who would have an indication for a GLP1 receptor agonist based on the SELECT trial criteria

Congress Presentation

About the speaker

Doctor Joan Torres Marques

Son Llatzer University Hospital, Palma de Mallorca (Spain)
0 follower

5 more presentations in this session

Discussants - Managing cardiovascular risk: pharmacological and digital tools

Thumbnail

Effect of statins on thoracic aortic disease: results from a meta-analysis and experimental data

Speaker: Doctor P. Poggio (Milan, IT)

Thumbnail

The CV polypill strategy (acetyl salicylic acid + atorvastatin + ramipril) as baseline treatment after a cardiovascular event supported by recent compelling evidence: a global expert consensus

Speaker: Professor A. Abreu (Lisbon, PT)

Thumbnail

Accuracy of nine artificial intelligence chatbots in replying in accordance with the 2023 ESH guidelines for the management of arterial hypertension

Speaker: Mr D. Tsounis (Nea Makri, GR)

Thumbnail

Effect of SGLT2 inhibitors in the management of moroccan patients with heart failure with reduced ejection fraction

Speaker: Professor N. Mouine (Rabat, MA)

Thumbnail

Access the full session

Poster session 1 - Managing cardiovascular risk: pharmacological and digital tools

Speakers: Doctor J. Torres Marques, Doctor P. Poggio, Professor A. Abreu, Mr D. Tsounis, Professor N. Mouine
Thumbnail

About the event

Image

ESC Preventive Cardiology 2024

25 April - 27 April 2024

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb